{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:19Z","timestamp":1789948819840,"version":"4.0.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":82,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16394-4","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T06:36:20Z","timestamp":1782887780000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PDCD1 gene polymorphisms linked with altered risk of female-specific hormone-dependent cancers: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Sabrina","family":"Zidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boutheina","family":"BenAbdelmoumenMardassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada","family":"Sahraoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassim Y.","family":"Almawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"16394_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216726","volume":"588","author":"M Gao","year":"2024","unstructured":"Gao M, Shi J, Xiao X, Yao Y, Chen X, Wang B, et al. PD-1 regulation in immune homeostasis and immunotherapy. Cancer Lett. 2024;588:216726. https:\/\/doi.org\/10.1016\/j.canlet.2024.216726.","journal-title":"Cancer Lett"},{"issue":"8","key":"16394_CR2","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1038\/s41375-024-02271-1","volume":"38","author":"M Farhat","year":"2024","unstructured":"Farhat M, Croft W, Parry HM, Verma K, Kinsella FAM, Xu J, Bone D, McSkeane T, Paneesha S, Pratt G, Moss P, Zuo J. PD-1 expression contributes to functional impairment of NK cells in patients with B-CLL. Leukemia. 2024;38(8):1813\u20137. https:\/\/doi.org\/10.1038\/s41375-024-02271-1.","journal-title":"Leukemia"},{"issue":"2","key":"16394_CR3","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.18632\/oncotarget.13895","volume":"8","author":"Y Dong","year":"2017","unstructured":"Dong Y, Sun Q, Zhang X. PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget. 2017;8(2):2171\u201386. https:\/\/doi.org\/10.18632\/oncotarget.13895.","journal-title":"Oncotarget"},{"issue":"3","key":"16394_CR4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18(3):153\u201367. https:\/\/doi.org\/10.1038\/nri.2017.108.","journal-title":"Nat Rev Immunol"},{"issue":"7655","key":"16394_CR5","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","volume":"545","author":"SR Gordon","year":"2017","unstructured":"Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, Gupta R, Tsai JM, Sinha R, Corey D, Ring AM, Connolly AJ, Weissman IL. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545(7655):495\u20139. https:\/\/doi.org\/10.1038\/nature22396.","journal-title":"Nature"},{"issue":"8","key":"16394_CR6","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00109-024-02463-3","volume":"102","author":"MA Ortega","year":"2024","unstructured":"Ortega MA, Boaru DL, De Leon-Oliva D, Fraile-Martinez O, Garc\u00eda-Montero C, Rios L, et al. PD-1\/PD-L1 axis: implications in immune regulation, cancer progression, and translational applications. J Mol Med (Berl). 2024;102(8):987\u20131000. https:\/\/doi.org\/10.1007\/s00109-024-02463-3.","journal-title":"J Mol Med (Berl)"},{"issue":"4","key":"16394_CR7","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1158\/1078-0432.CCR-23-2274","volume":"30","author":"T Denize","year":"2024","unstructured":"Denize T, Jegede OA, Matar S, El Ahmar N, West DJ, Walton E, et al. PD-1 expression on intratumoral regulatory T cells is associated with lack of benefit from anti-PD-1 therapy in metastatic clear-cell renal cell carcinoma patients. Clin Cancer Res. 2024;30(4):803\u201313. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2274.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"16394_CR8","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","volume":"5","author":"SL Topalian","year":"2019","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab. JAMA Oncol. 2019;5(10):1411\u201320. https:\/\/doi.org\/10.1001\/jamaoncol.2019.2187.","journal-title":"JAMA Oncol"},{"issue":"6","key":"16394_CR9","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.4049\/jimmunol.1502643","volume":"196","author":"AP Bally","year":"2016","unstructured":"Bally AP, Austin JW, Boss JM. Genetic and epigenetic regulation of PD-1 expression. J Immunol. 2016;196(6):2431\u20137. https:\/\/doi.org\/10.4049\/jimmunol.1502643.","journal-title":"J Immunol"},{"key":"16394_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1163633","volume":"14","author":"RY Chen","year":"2023","unstructured":"Chen RY, Zhu Y, Shen YY, Xu QY, Tang HY, Cui NX, et al. The role of PD-1 signaling in health and immune-related diseases. Front Immunol. 2023;14:1163633. https:\/\/doi.org\/10.3389\/fimmu.2023.1163633.","journal-title":"Front Immunol"},{"issue":"7","key":"16394_CR11","first-page":"1203","volume":"30","author":"J Gao","year":"2024","unstructured":"Gao J, Ward JF, Pettaway CA, Shi LZ. PD-1 and its ligands in cancer immunity and immunotherapy. Clin Cancer Res. 2024;30(7):1203\u201315.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"16394_CR12","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s42003-020-0845-0","volume":"3","author":"N Patsoukis","year":"2020","unstructured":"Patsoukis N, Duke-Cohan JS, Chaudhri A, Aksoylar HI, Wang Q, Council A, Berg A, Freeman GJ, Boussiotis VA. Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation. Commun Biol. 2020;3(1):128. https:\/\/doi.org\/10.1038\/s42003-020-0845-0.","journal-title":"Commun Biol"},{"issue":"7","key":"16394_CR13","doi-asserted-by":"publisher","first-page":"6279","DOI":"10.1007\/s11033-023-08423-3","volume":"50","author":"K Boguszewska-Byczkiewicz","year":"2023","unstructured":"Boguszewska-Byczkiewicz K, Wow T, Szyma\u0144ska B, Kosny M, Kolacinska-Wow A. The PD-1 single-nucleotide polymorphism rs11568821 and rs2227981 as a novel prognosis model in a triple-negative breast cancer patient. Mol Biol Rep. 2023;50(7):6279\u201385. https:\/\/doi.org\/10.1007\/s11033-023-08423-3.","journal-title":"Mol Biol Rep"},{"issue":"10","key":"16394_CR14","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.31557\/APJCP.2020.21.10.3115","volume":"21","author":"S Karami","year":"2020","unstructured":"Karami S, Sattarifard H, Kiumarsi M, Sarabandi S, Taheri M, Hashemi M, et al. Evaluating the possible association between PD-1 (Rs11568821, Rs2227981, Rs2227982) and PD-L1 (Rs4143815, Rs2890658) polymorphisms and susceptibility to breast cancer in a sample of southeast Iranian women. Asian Pac J Cancer Prev. 2020;21(10):3115\u201323. https:\/\/doi.org\/10.31557\/APJCP.2020.21.10.3115.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"8","key":"16394_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081150","volume":"11","author":"M Hashemi","year":"2019","unstructured":"Hashemi M, Karami S, Sarabandi S, Moazeni-Roodi A, Ma\u0142ecki A, Ghavami S, et al. Association between PD-1 and PD-L1 polymorphisms and the risk of cancer: a meta-analysis of case-control studies. Cancers (Basel). 2019;11(8):1150. https:\/\/doi.org\/10.3390\/cancers11081150.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"16394_CR16","first-page":"245","volume":"12","author":"L Yang","year":"2024","unstructured":"Yang L, Wang B, Chen L, et al. Genetic polymorphisms in immune checkpoint genes and cancer susceptibility: A systematic review. Cancer Immunol Res. 2024;12(3):245\u201360.","journal-title":"Cancer Immunol Res"},{"key":"16394_CR17","doi-asserted-by":"publisher","DOI":"10.4238\/gmr.15016357","author":"XF Li","year":"2016","unstructured":"Li XF, Jiang XQ, Zhang JW, Jia YJ. Association of the programmed cell death-1 PD1.5 C\u2009>\u2009T polymorphism with cervical cancer risk in a Chinese population. Genet Mol Res. 2016. https:\/\/doi.org\/10.4238\/gmr.15016357.","journal-title":"Genet Mol Res"},{"issue":"2","key":"16394_CR18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cellimm.2015.01.018","volume":"294","author":"S Kovats","year":"2015","unstructured":"Kovats S. Estrogen receptors regulate innate immune cells and signaling pathways. Cell Immunol. 2015;294(2):63\u20139. https:\/\/doi.org\/10.1016\/j.cellimm.2015.01.018.","journal-title":"Cell Immunol"},{"issue":"4","key":"16394_CR19","first-page":"298","volume":"45","author":"D McGuinness","year":"2024","unstructured":"McGuinness D, Britt KL. The role of sex hormones in immune regulation and cancer development. Trends Immunol. 2024;45(4):298\u2013312.","journal-title":"Trends Immunol"},{"issue":"5","key":"16394_CR20","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrc.2016.30","volume":"16","author":"A Clocchiatti","year":"2016","unstructured":"Clocchiatti A, Cora E, Zhang Y, Dotto GP. Sexual dimorphism in cancer. Nat Rev Cancer. 2016;16(5):330\u20139. https:\/\/doi.org\/10.1038\/nrc.2016.30.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"16394_CR21","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00251-017-1015-5","volume":"70","author":"A Salmaninejad","year":"2018","unstructured":"Salmaninejad A, Khoramshahi V, Azani A, Soltaninejad E, Aslani S, Zamani MR, et al. PD-1 and cancer: molecular mechanisms and polymorphisms. Immunogenetics. 2018;70(2):73\u201386. https:\/\/doi.org\/10.1007\/s00251-017-1015-5.","journal-title":"Immunogenetics"},{"issue":"7","key":"16394_CR22","doi-asserted-by":"publisher","first-page":"6068","DOI":"10.18632\/aging.205689","volume":"16","author":"M Yang","year":"2024","unstructured":"Yang M, Liu Y, Zheng S, Geng P, He T, Lu L, Feng Y, Jiang Q. Associations of PD-1 and PD-L1 gene polymorphisms with cancer risk: a meta-analysis based on 50 studies. Aging. 2024;16(7):6068\u201397. https:\/\/doi.org\/10.18632\/aging.205689.","journal-title":"Aging"},{"key":"16394_CR23","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.ygyno.2009.10.084","volume":"116","author":"EL Ivansson","year":"2010","unstructured":"Ivansson EL, Juko-Pecirep I, Gyllensten UB. Interaction of immunological genes on chromosome 2q33 and IFNG in susceptibility to cervical cancer. Gynecol Oncol. 2010;116:544\u20138.","journal-title":"Gynecol Oncol"},{"key":"16394_CR24","doi-asserted-by":"publisher","first-page":"4205","DOI":"10.1007\/s11033-010-0542-z","volume":"38","author":"MR Haghshenas","year":"2011","unstructured":"Haghshenas MR, Naeimi S, Talei A, Ghaderi A, Erfani N. Program death 1 (PD1) haplotyping in patients with breast carcinoma. Mol Biol Rep. 2011;38:4205\u201310.","journal-title":"Mol Biol Rep"},{"key":"16394_CR25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s10549-011-1440-3","volume":"129","author":"Z Hua","year":"2011","unstructured":"Hua Z, Li D, Xiang G, Xu F, Jie G, Fu Z, et al. PD-1 polymorphisms are associated with sporadic breast cancer in Chinese Han population of Northeast China. Breast Cancer Res Treat. 2011;129:195\u2013201.","journal-title":"Breast Cancer Res Treat"},{"key":"16394_CR26","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ygyno.2016.11.010","volume":"144","author":"Y Li","year":"2017","unstructured":"Li Y, Zhang HL, Kang S, Zhou RM, Wang N. The effect of polymorphisms in PD-1 gene on the risk of epithelial ovarian cancer and patients\u2019 outcomes. Gynecol Oncol. 2017;144:140\u20135.","journal-title":"Gynecol Oncol"},{"key":"16394_CR27","doi-asserted-by":"publisher","unstructured":"Fattahi MJ, Momtahan M, Poostkar M, Shiravani Z, Erfani N, Haghshenas MR, et al. Investigation of PD-1 gene variants in patients with endometrial cancer: a case-control study. J Turk Soc Obstet Gynecol. 2024(2). https:\/\/doi.org\/10.4274\/tjod.galenos.2024.71508.","DOI":"10.4274\/tjod.galenos.2024.71508"},{"issue":"21","key":"16394_CR28","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003760","volume":"95","author":"HT Ren","year":"2016","unstructured":"Ren HT, Li YM, Wang XJ, Kang HF, Jin TB, Ma XB, et al. PD-1 rs2227982 polymorphism is associated with the decreased risk of breast cancer in Northwest Chinese women: a hospital-based observational study. Medicine (Baltimore). 2016;95(21):e3760. https:\/\/doi.org\/10.1097\/MD.0000000000003760.","journal-title":"Medicine (Baltimore)"},{"key":"16394_CR29","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3233\/CBM-170357","volume":"21","author":"D Tan","year":"2018","unstructured":"Tan D, Sheng L, Yi QH. Correlation of PD-1\/PD-L1 polymorphisms and expressions with clinicopathologic features and prognosis of ovarian cancer. Cancer Biomark. 2018;21:287\u201397.","journal-title":"Cancer Biomark"},{"key":"16394_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.genrep.2024.102096","volume":"38","author":"M Kakavandi","year":"2025","unstructured":"Kakavandi M, Bafrani MH, Mahabadi JA, Bafrani HH. Investigating the relationship between polymorphisms pd1.9 and rs7421861 of PD1 gene with breast cancer. Gene Rep. 2025;38:102096.","journal-title":"Gene Rep"},{"key":"16394_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2024.106517","volume":"240","author":"C McGuinness","year":"2024","unstructured":"McGuinness C, Britt KL. Estrogen receptor regulation of the immune microenvironment in breast cancer. J Steroid Biochem Mol Biol. 2024;240:106517. https:\/\/doi.org\/10.1016\/j.jsbmb.2024.106517.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"3","key":"16394_CR32","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/j.1365-2265.2008.03337.x","volume":"70","author":"I Ezzidi","year":"2009","unstructured":"Ezzidi I, Mtiraoui N, Kacem M, Mallat SG, Mohamed MB, Chaieb M, et al. Interleukin-10-592C\/A, -819C\/T and \u2212\u20091082A\/G promoter variants affect the susceptibility to nephropathy in Tunisian type 2 diabetes (T2DM) patients. Clin Endocrinol (Oxf). 2009;70(3):401\u20137. https:\/\/doi.org\/10.1111\/j.1365-2265.2008.03337.x.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"16394_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cyto.2018.03.003","volume":"106","author":"N Sellami","year":"2018","unstructured":"Sellami N, Lamine LB, Turki A, Sarray S, Jailani M, Al-Ansari AK, et al. Association of VEGFA variants with altered VEGF secretion and type 2 diabetes: a case-control study. Cytokine. 2018;106:29\u201334. https:\/\/doi.org\/10.1016\/j.cyto.2018.03.003.","journal-title":"Cytokine"},{"key":"16394_CR34","doi-asserted-by":"publisher","first-page":"e0152448","DOI":"10.1371\/journal.pone.0152448","volume":"11","author":"W Dong","year":"2016","unstructured":"Dong W, Gong M, Shi Z, Xiao J, Zhang J, Peng J. Programmed Cell Death-1 Polymorphisms Decrease the Cancer Risk: A Meta-Analysis Involving Twelve Case-Control Studies. PLoS ONE. 2016;11:e0152448.","journal-title":"PLoS ONE"},{"key":"16394_CR35","first-page":"22278","volume":"8","author":"W Tang","year":"2015","unstructured":"Tang W, Wang Y, Jiang H, Liu P, Liu C, Gu H, et al. Programmed death-1 (PD-1) rs2227981 C\u2009>\u2009T polymorphism is associated with cancer susceptibility: a meta-analysis. Int J Clin Exp Med. 2015;8:22278\u201385.","journal-title":"Int J Clin Exp Med"},{"key":"16394_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.558757","volume":"11","author":"Q Liu","year":"2020","unstructured":"Liu Q, Cheng R, Kong X, Wang Z, Fang Y, Wang J. Molecular and clinical characterization of PD-1 in breast cancer using large-scale transcriptome data. Front Immunol. 2020;11:558757. https:\/\/doi.org\/10.3389\/fimmu.2020.558757.","journal-title":"Front Immunol"},{"issue":"1","key":"16394_CR37","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20202726","volume":"41","author":"M Dallel","year":"2021","unstructured":"Dallel M, Douma Z, Finan RR, Hachani F, Letaifa DB, Mahjoub T, et al. Contrasting association of leptin receptor polymorphisms and haplotypes with polycystic ovary syndrome in Bahraini and Tunisian women: a case-control study. Biosci Rep. 2021;41(1):BSR20202726. https:\/\/doi.org\/10.1042\/BSR20202726.","journal-title":"Biosci Rep"},{"key":"16394_CR38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.gene.2019.01.032","volume":"694","author":"M Dallel","year":"2019","unstructured":"Dallel M, Sghaier I, Finan RR, Douma Z, Hachani F, Letaifa DB, et al. Circulating leptin concentration, LEP gene variants and haplotypes, and polycystic ovary syndrome in Bahraini and Tunisian Arab women. Gene. 2019;694:19\u201325. https:\/\/doi.org\/10.1016\/j.gene.2019.01.032.","journal-title":"Gene"},{"key":"16394_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00914","volume":"10","author":"S Allouch","year":"2020","unstructured":"Allouch S, Malki A, Allouch A, Gupta I, Vranic S, Al Moustafa AE. High-risk HPV oncoproteins and PD-1\/PD-L1 interplay in human cervical cancer: recent evidence and future directions. Front Oncol. 2020;10:914. https:\/\/doi.org\/10.3389\/fonc.2020.00914.","journal-title":"Front Oncol"},{"issue":"10","key":"16394_CR40","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1038\/s41590-024-01961-3","volume":"25","author":"SA Weiss","year":"2024","unstructured":"Weiss SA, Huang AY, Fung ME, Martinez D, Chen ACY, LaSalle TJ, et al. Epigenetic tuning of PD-1 expression improves exhausted T cell function and viral control. Nat Immunol. 2024;25(10):1871\u201383. https:\/\/doi.org\/10.1038\/s41590-024-01961-3.","journal-title":"Nat Immunol"},{"issue":"11","key":"16394_CR41","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1016\/j.prp.2018.09.015","volume":"214","author":"LS Da","year":"2018","unstructured":"Da LS, Zhang Y, Zhang CJ, Bu LJ, Zhu YZ, Ma T, et al. The PD-1 rs36084323 A\u2009>\u2009G polymorphism decrease cancer risk in Asian: a meta-analysis. Pathol Res Pract. 2018;214(11):1758\u201364. https:\/\/doi.org\/10.1016\/j.prp.2018.09.015.","journal-title":"Pathol Res Pract"},{"issue":"1","key":"16394_CR42","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1364828","volume":"7","author":"S Simon","year":"2017","unstructured":"Simon S, Labarriere N. PD-1 expression on tumor-specific T cells: friend or foe for immunotherapy? Oncoimmunology. 2017;7(1):e1364828. https:\/\/doi.org\/10.1080\/2162402X.2017.1364828.","journal-title":"Oncoimmunology"},{"issue":"6477","key":"16394_CR43","doi-asserted-by":"publisher","DOI":"10.1126\/science.aax0182","volume":"367","author":"SL Topalian","year":"2019","unstructured":"Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 2019;367(6477):eaax0182.","journal-title":"Science"},{"key":"16394_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1653990","volume":"15","author":"M Specchia","year":"2025","unstructured":"Specchia M, Siringo M, Mazzotti E, Mazzuca F. Relationship between single-nucleotide polymorphisms and cancer immunotherapy efficacy and toxicity: a systematic review. Front Oncol. 2025;15:1653990. https:\/\/doi.org\/10.3389\/fonc.2025.1653990.","journal-title":"Front Oncol"},{"issue":"1","key":"16394_CR45","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-023-01725-x","volume":"22","author":"H Zhang","year":"2023","unstructured":"Zhang H, Liu L, Liu J, Dang P, Hu S, Yuan W, et al. Roles of tumor-associated macrophages in anti-PD-1\/PD-L1 immunotherapy for solid cancers. Mol Cancer. 2023;22(1):58.","journal-title":"Mol Cancer"},{"key":"16394_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.731798","volume":"12","author":"J Liu","year":"2021","unstructured":"Liu J, Chen Z, Li Y, Zhao W, Wu J, Zhang Z. PD-1\/PD-L1 checkpoint inhibitors in tumor immunotherapy. Front Pharmacol. 2021;12:731798. https:\/\/doi.org\/10.3389\/fphar.2021.731798.","journal-title":"Front Pharmacol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16394-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16394-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16394-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T23:01:31Z","timestamp":1789945291000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16394-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16394"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16394-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"9 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No patient consent or ethical approval was required, as the analyses were based on previously published studies.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1124"}}